An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

In a small trial across ten U.S. research sites, a novel HIV vaccine candidate has shown a result that has eluded scientists ...

Recent developments in antiretroviral therapy (ART) include longer-acting therapies that don't require a daily oral pill and ...

Q2 2025 Management View CEO Daniel P. O'Day opened the call by highlighting "the FDA approval of lenacapavir or Yeztugo for twice yearly HIV prevention," describing it as "a milestone moment in the ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

EMA recommends Gilead Sciences' Lenacapavir for HIV prevention, with FDA approval and generic options available soon.

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV. Scientists say this ...

Lenacapavir had been approved in 2022 to treat certain HIV infections and, in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection ...

Lenacapavir had been approved in 2022 to treat certain HIV infections and, in trials for prevention, it was found to dramatically reduce the risk of infection and provide almost total protection ...

A pharmacist holds a vial of lenacapavir, the new HIV prevention injectable drug, at the Desmond Tutu Health Foundation's Masiphumelele Research Site, in Cape Town, South Africa, Tuesday, July 23 ...